April, 2024
April 2024
Joshua Schiffman: Thank you Peter Adamson and Sanofi for this critically important and essential effort
Feb 18, 2024, 14:16

Joshua Schiffman: Thank you Peter Adamson and Sanofi for this critically important and essential effort

Joshua Schiffman, CEO and Co-Founder of Peel Therapeutics, recently shared a post by Peter Adamson, Global Head of Oncology Development and Pediatric Innovation at Sanofi, on LinkedIn, adding:

“No child left behind! Thank you, Peter Adamson and Sanofi for this critically important and essential effort.”

Quoting Peter Adamson’s post:

“International Childhood Cancer Day: The Power of Collaboration

Today, International Childhood Cancer Day is a time to highlight the ongoing battle against childhood cancer, a leading cause of death in the pediatric population. Despite advances, more effective and less toxic treatments are needed. Future progress may best be made with further investment in research and, importantly, through deeper collaborations and partnerships.

Within Sanofi’s R&D Childhood Cancer program, we are committed to improving the outcome of children with cancer, and to build strong partnerships across the community. Ongoing efforts include a systematic evaluation of Sanofi’s internal drug development pipeline, with a focus on identifying targets and pathways particularly relevant to childhood cancer early in the R&D value chain. Preclinical studies are conducted to gain better insight and validate initial findings. Moreover, we want to shorten the timeline to start select clinical trials for high priority drugs. In 2023, we were able to do this for one of our investigational drugs, starting a pediatric specific cohort while the adult phase 1 trial is ongoing.

Strategic partnerships and collaborations have been initiated in several realms. Sanofi entered agreements with the International Therapies for Children with Cancer (ITCC), the Foundation for the National Institute of Health (FNIH) COACH consortia, and in 2023, we launched a Childhood Cancer Working Group at the Paris Saclay Cancer Cluster (PSCC). These collaborations aim to discover innovative solutions and potential new treatments for children with cancer.

Sanofi’s R&D Childhood Cancer program complements Foundation’s My Child Matters program, which specifically addresses the challenges faced by children with cancer and their families in low and middle-income countries. Through collaborative efforts and partnerships, Sanofi is committed to advancing research and improving outcomes for children battling cancer worldwide.

I would like to express my sincere thanks to all the many people who work tirelessly towards improving the outcome for children with cancer. Together we can make impact.”

Sources: Joshua Schiffman/LinkedIn and Peter Adamson/LinkedIn